相关实验视频
Updated: Jan 13, 2026

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.9K
阿尔茨海默病中的粉样β和陶氏体:病原,机制和相互作用
Altaf A Abdulkhaliq1, Bonglee Kim2, Yousef M Almoghrabi3,4
1Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia.
Cell death & disease
|January 9, 2026
概括
阿尔茨海默病 (AD) 涉及粉样β斑块和陶,导致认知能力下降. 本综述探讨了它们对AD病原和治疗策略的综合影响.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 痴呆症研究 痴呆症研究
背景情况:
- 阿尔茨海默病 (AD) 是最常见的痴呆症,其特征是粉样β斑块和团.
- 早期症状包括突触功能障碍,进展到神经退行和记忆丧失.
- 阿尔茨海默病经常被误诊为老年人的正常衰老.
研究的目的:
- 审查最近在了解阿米洛伊德β和病理学方面取得的进展.
- 批判性地讨论阿米洛伊德β和陶在阿尔茨海默病发病过程中的相互作用和协同效应.
- 为AD研究和治疗开发提供新的视角.
主要方法:
- 关于阿尔茨海默病病理学的最新研究的文献综述.
- 专注于粉样β和的病理足迹.
- 分析了粉样β和陶之间的协同作用.
主要成果:
- 粉样β和陶蛋白是阿尔茨海默病的关键病理特征.
- 粉样β和蛋白之间的相互作用显著促进神经退行.
- 了解这种相互作用对于开发有效的AD治疗至关重要.
结论:
- 最近的研究强调了粉样β和的相互作用在阿尔茨海默病中的关键作用.
- 对这些病理特征的进一步调查可能会打开新的治疗目标.
- 本综述提供了指导未来阿尔茨海默病研究和治疗的见解.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Amyloid Fibrils
6.3K
6.3K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806

